Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Chenlei Wen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3458-5409; OpenAlex author ID A5071527179. Sources: OpenAlex.

Their work

Papers
27 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
87
Papers, trials and grants by year

2016: 1 paper · 2017: 4 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 4 papers · 2025: 5 papers · 2026: 3 papers

Papers 27

  1. Longitudinal analysis of circulating tumor DNA and CA19-9 dynamics in predicting disease relapse and monitoring treatment response in stage I-III pancreatic du… Co-author DOI 10.1016/j.ejca.2026.117042↗
  2. Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observational Study. First author DOI 10.1097/mpa.0000000000002511↗
  3. FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1001↗
  4. H19 promotes polarization and alternative splicing in tumor-associated macrophages, facilitating pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2024.217389↗
  5. Irreversible electroporation combined with PD-L1/IL-6 dual blockade promotes anti-tumor immunity via cDC2/CD4+T cell axis in MHC-I deficient pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217620↗
  6. Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. Co-author DOI 10.1016/j.xpro.2025.103635↗
  7. Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemoresistance in PDAC. Co-author DOI 10.1016/j.ymthe.2025.09.004↗
  8. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Co-author DOI 10.1038/s41418-024-01423-1↗
  9. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  10. Gasdermin C promotes Stemness and Immune Evasion in Pancreatic Cancer via Pyroptosis-Independent Mechanism. Co-author DOI 10.1002/advs.202308990↗
  11. Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. Co-author DOI 10.1016/j.canlet.2024.217134↗
  12. CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. Co-author DOI 10.1016/j.xcrm.2024.101692↗
  13. Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer: Results from a longitudinal cohort and mendelian rando… Co-author DOI 10.1016/j.lanwpc.2022.100596↗
  14. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000264↗
  15. Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multice… Co-author DOI 10.7150/thno.84978↗
  16. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study. Co-author DOI 10.1186/s12885-022-09719-6↗
  17. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-022-01272-w↗
  18. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. First author DOI 10.1016/j.ebiom.2021.103716↗
  19. A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.634881↗
  20. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3425↗
  21. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914557116↗
  22. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0965-3↗
  23. MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2016.12.167↗
  24. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.012↗
  25. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic … Co-author DOI 10.1186/s12943-017-0738-0↗
  26. Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance. First author DOI 10.3892/or.2017.6026↗
  27. mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.7375↗

Closest collaborators

The 25 strongest of 87 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 18 shared papers, 2017–2026 · strength 2.78
  2. Xiaxing Deng · 10 shared papers, 2016–2026 · strength 1.32
  3. Chenghong Peng · 11 shared papers, 2016–2024 · strength 1.05
  4. Siyi Zou · 7 shared papers, 2021–2025 · strength 1.00
  5. Berina Šabanović · 5 shared papers, 2024–2026 · strength 0.96
  6. Christopher Heeschen · 5 shared papers, 2024–2026 · strength 0.96
  7. Lingxi Jiang · 5 shared papers, 2023–2026 · strength 0.94
  8. Baiyong Shen · 7 shared papers, 2016–2025 · strength 0.89
  9. Qian Zhan · 4 shared papers, 2022–2026 · strength 0.89
  10. Yizhi Cao · 5 shared papers, 2022–2025 · strength 0.83
  11. Xiongxiong Lu · 8 shared papers, 2016–2023 · strength 0.76
  12. Quan Zheng · 4 shared papers, 2024–2025 · strength 0.72
  13. Shuyu Zhai · 4 shared papers, 2023–2025 · strength 0.69
  14. Hao Chen · 7 shared papers, 2016–2022 · strength 0.65
  15. Qian Zhan · 6 shared papers, 2017–2022 · strength 0.59
  16. Xiaomei Tang · 7 shared papers, 2016–2024 · strength 0.57
  17. Dongfeng Cheng · 5 shared papers, 2017–2024 · strength 0.53
  18. Da Fu · 3 shared papers, 2024–2025 · strength 0.50
  19. Pengyi Liu · 3 shared papers, 2022–2025 · strength 0.47
  20. Xinjing Wang · 6 shared papers, 2016–2022 · strength 0.47
  21. Jiancheng Wang · 4 shared papers, 2020–2023 · strength 0.45
  22. Jingwei Li · 2 shared papers, 2025–2026 · strength 0.45
  23. Hao Chen · 3 shared papers, 2017–2024 · strength 0.40
  24. Jiayu Lin · 2 shared papers, 2025 · strength 0.39
  25. Yang Liu · 2 shared papers, 2024–2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.